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OBJECTIVES: Prior research has established that the rapid growth in health care 
costs is due in large part to the introduction of effective but expensive medical 
technologies covered by insurance. At the same time, anecdotal evidence 
suggests that relatively inexpensive technologies not covered by insurance might 
provide some relief to the ongoing escalation in health care costs. Lack of 
reimbursement often limits incentives for use. This study compares the evidence 
of cost-effectiveness of the most highly utilized reimbursable therapies, such as 
metformin, simvastatin and amlodipine, with similarly low-cost, non-
reimbursed therapies including oral nutritional supplements, low-dose aspirin, 
and hand hygiene programs. METHODS: The analysis utilized the Tufts Cost-
Effectiveness Analysis Registry, a comprehensive database of 3,067 cost-utility 
studies on a wide variety of diseases and treatments published from 1976-2011. 
Additional studies were collected from searches via PubMed. The mean 
incremental cost per QALY was calculated for all interventions evaluated and 
included in the registry. For studies not in the registry, the costs and benefits 
across these studies were incorporated. RESULTS: The mean cost per QALY from 
the 26 studies evaluating reimbursable therapies was $26,212. Of these, 14% of 
studies showed these as cost-saving (dominant) interventions, 53% as falling 
below $50k per QALY and 33% above $50k per QALY. Of the non-reimbursed 
interventions, the mean cost per QALY was $8,245; of these, 34% were shown to 
be cost-saving and 66% as below $50k per QALY. CONCLUSIONS: Results suggest 
that expensive technology is not the only way to achieve meaningful health 
improvements. Moreover, evidence suggests that many of these non-reimbursed 
technologies are not utilized as widely as those that are commonly reimbursed. 
Measures to encourage greater utilization in appropriate circumstances, 
including reimbursement policies that reward appropriate uses of such 
technologies, have the potential both to restrain cost growth and improve the 
quality of care.  
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OBJECTIVES: In various emerging markets coverage of branded drugs is 
centralized using a national formulary list of covered products. Among new 
branded products, pricing and coverage of expensive cancer dugs has been 
undergoing significant change in various emerging markets. The objective of this 
study was to understand new trends in pricing and coverage of targeted cancer 
therapies in Russia. METHODS: To understand the changes in coverage of 
targeted cancer therapies, the 2011 and 2012 essential drugs lists for Russia were 
analyzed for ATC codes L01XC, L01XE, L01XX, L04AA and L04AX. The newly 
covered and non-covered products were identified and analyzed for factors 
driving the change in coverage policy. For selected analogs price change during 
2011 and 2012 was analyzed to understand trends in price set by the 
government. RESULTS: Analysis of 2011-2012 essential drug lists show 
significant change in coverage of targeted cancer therapies. In 2011, only 5 
targeted cancer therapies were covered in the essential drug list (Bevacizumab, 
Rituximab, Trastuzumab, Imatinib and Bortezomib). In 2012, an additional 8 
branded cancer drugs were added to the list, expanding the coverage of targeted 
cancer therapies to 13 products. The price change trend for selected analogs 
show some products covered at the same price, while for others price was 
reduced by 5-10%. For example, one of the covered monoclonal antibodies price 
did not change during 2011 and 2012, while prices for a proteasome inhibitor and 
a tyrosine kinase inhibitor were lowered by 6% and 10%, respectively. 
CONCLUSIONS: Analysis of pricing and coverage of targeted cancer therapies in 
Russia shows expansion of access of several products.  
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OBJECTIVES: With the passage of the Affordable Care Act and broader concerns 
with health care costs in the US, physicians and hospitals will be assuming more 
risk for the cost and quality of health care. They will be doing so through 
delivery reform programs, such as accountable care organizations and bundled 
payment programs. While the implications of these delivery models for health 
care costs have been identified, their potential impact on patient outcomes is not 
well understood. This analysis sought to review how changes to payment 
mechanisms over the last 20 years have impacted patient outcomes in the US. 
METHODS: A literature review was undertaken to examine the impact that non-
fee for service reimbursement has had on patient outcomes. Ninety-seven 
articles which compared fee-for-service to other reimbursement mechanisms in 
the US were identified, of which 58 reported on patient outcomes. Non fee-for-
service reimbursement mechanisms considered in this analysis included 
bundled payments, capitated payments, prepaid plans and managed care as 
distinct from fee-for-service, although the exact details of remuneration under 
these alternative payment systems were not specified. RESULTS: Overall 62% of 
studies provided evidence that fee-for-service reimbursement delivered better 
patient outcomes. Analysis showed that non fee-for-service reimbursement may 
work well for younger, healthier patients, while sicker patients with multiple 
chronic conditions had better outcomes under traditional fee-for-service. 
CONCLUSIONS: This literature review provides preliminary data on the impact 
that risk shifting to providers may have on patient outcomes, with evidence 
pointing to the most vulnerable patients having inferior outcomes under non 
fee-for-services as compared to those in fee-for-service. In addition, few studies 
considered the long-term impact of changing financial incentives on patient 
outcomes. As public and private payers in the United States embrace new 
mechanisms of payment, great care must be taken to understand the 
implications on patient outcomes especially among the most vulnerable.  
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OBJECTIVES: During 2011-2012 significant price cuts were implemented in 
various markets in the European Union. These price cuts have introduced new 
pricing dynamics affecting reference pricing and intra-EU parallel export of 
expensive drugs. METHODS: To understand new pricing dynamics in the big five 
EU (UK, France, Germany, Italy and Spain) we analyzed the trend in pricing for 
branded and biosimilar GM-CSF products. Prices were analyzed for percentage 
discount compared to branded GM-CSF product and relative price levels in five 
selected markets. Recent reimbursement policy changes and price cuts were also 
analyzed. RESULTS: The 2012 prices for GM-CSF products show significant 
variation across the UK, France, Germany, Italy and Spain. The prices for GM-CSF 
products were dramatically lower in Spain and the UK compared to France, 
Germany and Italy. For example, for branded GM-CSF product prices in Spain 
were 80% lower than prices in the UK. Similarly, the prices for biosimilar GM-CSF 
products were 72% lower in Spain than in the UK. The percentage price discount 
for biosimilar products versus branded product also shows large variation in big 
five EU markets. For example, Spain and the UK prices were almost at parity 
while the prices in France, Germany, and Italy showed 12%, 31% and 26% 
discount, respectively. CONCLUSIONS: Recent pricing reforms have significantly 
changed the pricing dynamic across the big five EU markets. Case study of GM-
CSF products illustrates wide variation in pricing for branded and biosimilar 
products.  
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OBJECTIVES: Obtaining early payer inputs, either formally or informally, as a 
part of the clinical development process for new drugs, is routinely possible in 
some western reimbursed countries. However, a striking absence of such 
interaction was noted in the ‘emerging markets’ even where HTA processes are 
now in place. The objective was to understand payer-industry dynamics better in 
specific emerging markets and gauge the potential model that can be proposed 
for early payer engagement in these countries METHODS: A comparison of 
current practices between select ‘emerging markets’, (in Asia - China, S.Korea 
and Taiwan and in Latin America - Brazil, Mexico), and in the developed 
countries - UK, Germany, Sweden and Canada was first conducted based on 
secondary research. This was then followed by interviews with academics, 
clinical KOLs, payers and government advisers. A semi-quantitative scoring 
system was used to analyse present potential solutions to improve collaborative 
working in the future. RESULTS: In contrast to developed countries, the mixture 
of current availability of early engagement across the ‘emerging markets’ 
consists only of either informal mechanisms or none at all. A formal process for 
direct consultation is not presently an option in the Asian markets although 
informal routes can be considered in some. CONITEC (Brazil) has a mechanism 
outlined although the specificity of feedback was considered low. Local interest 
and mechanisms for early payer engagement were thought to be an option only 
if aspects such as local relevance of the comparator and the target population 
are increasingly incorporated into clinical development plans. CONCLUSIONS: 
Directly applying western models of engagement with payers will not necessarily 
work in these countries. Encouraging tailored payer engagement practices at the 
country level which manufacturers then increased incorporation of the advice in 
a commercially relevant manner should work.  
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OBJECTIVES: To analyze the reimbursement appraisals of manufacturers’ 
Pharmaceutical Benefits Scheme (PBS) submissions, through the Public Summary 
Documents, in Australia from 2005-2012 to identify trends and issues within the 
appraisals over time. METHODS: Since 2005, relatively detailed information on 
the PBAC reimbursement submission appraisals of all major manufacturers’ 
submissions was made public in the form of Public Summary Documents (PSD) 
available as PDFs. A proprietary database has been created to digitally enter and 
organize this information utilizing key words/phrases as variables. This database 
was used to undertake a retrospective review of PSD’s. The following broad 
categories were used to analyse trends: clinical evidence, economic evaluations 
and methodology. RESULTS: At time of writing, there were a total of 547, 
excluding special reviews/other atypical documents, and 533 were analyzable 
(97%). There were an average of 25.4 PSDs per meeting and 76.1 PSDs per year (no 
increasing trend). Clinical Evidence: Uncertainty in evidence was evident in 69% 
of PSD’s (increasing trend), use of indirect comparisons 33% (no clear trend) and 
use of meta-analysis 27% (no clear trend). Economic Evaluations: Cost-
minimization versus cost-effectiveness were used almost equally 43% versus 
